Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-003337-40-BE
EUCTR2005-003337-40-BE
Active, not recruiting
Not Applicable

A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Not provided0 sitesMay 20, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCrohn's Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Crohn's Disease
Sponsor
Not provided
Status
Active, not recruiting
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 20, 2010
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Not provided

Eligibility Criteria

Inclusion Criteria

  • •\- age between 18 and 50 years
  • •\- confirmed diagnosis of active Crohn's Disease
  • •\- unsatisfactory course despite 3 immunosuppressive agents in addition to corticosteroids
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- BMI \< 18
  • •\- concomitant severe disease
  • •\- infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying of progression or recurrences in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastases
EUCTR2004-001101-10-GBovartis Pharmaceuticals UK Ltd446
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung cancerPrevention of bone metastasis in patients with non small cell lung cancer Stage III.MedDRA version: 6.1Level: PTClassification code 10029519
EUCTR2004-001101-10-ITOVARTIS FARMA
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancer
EUCTR2004-001101-10-HUovartis Pharma Services AG446
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastases
EUCTR2004-001101-10-BEovartis Pharma Services AG446
Active, not recruiting
Not Applicable
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastases
EUCTR2004-001101-10-ATovartis Pharma Services AG446